Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society.
作者信息
Oelke Matthias, Gravas Stavros
出版信息
World J Urol. 2010 Feb;28(1):1-2. doi: 10.1007/s00345-010-0507-9.
Abstract
摘要
相似文献
1
Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society.
World J Urol. 2010 Feb;28(1):1-2. doi: 10.1007/s00345-010-0507-9.
2
A plea for higher-quality data for GreenLight laser technology in the context of surgical benign prostatic obstruction trials: the GOLIATH study-fact or fiction in the era of evidence-based urology?
Eur Urol. 2014 May;65(5):943-5. doi: 10.1016/j.eururo.2013.11.037. Epub 2013 Dec 2.
3
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.泌尿科医生和初级保健医生对良性前列腺增生的评估和管理：来自观察性 BPH 登记处的实践模式。
J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24.
4
Reply from authors re: Charalampos Mamoulakis. A plea for higher-quality data for GreenLight laser technology in the context of surgical benign prostatic obstruction trials: the GOLIATH study-fact or fiction in the era of evidence-based urology? Eur Urol 2014;65:943-5.
Eur Urol. 2014 May;65(5):945-6. doi: 10.1016/j.eururo.2013.12.013. Epub 2013 Dec 21.
5
Special Issue: Current practices in the management of benign prostatic hyperplasia. Introduction.
BJU Int. 2008 Nov;102 Suppl 2:1-2. doi: 10.1111/j.1464-410X.2008.08085.x.
6
Facilitating the medical management of benign prostatic hyperplasia in primary care.
BJU Int. 2010 Jan;105(1):131-2. doi: 10.1111/j.1464-410X.2009.09112_2.x.
7
Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.良性前列腺增生症患者下尿路症状与血清性激素水平的关系。
BJU Int. 2010 Dec;106(11):1700-3. doi: 10.1111/j.1464-410X.2010.09459.x.
8
Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.良性前列腺增生相关下尿路症状治疗的性影响。
Curr Urol Rep. 2010 Jul;11(4):228-35. doi: 10.1007/s11934-010-0112-x.
9
Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia.动脉硬化相关因素与症状性良性前列腺增生的阻力指数无临床显著相关性。
Urology. 2011 Feb;77(2):433-7. doi: 10.1016/j.urology.2010.04.065. Epub 2010 Dec 18.
10
Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Eur Urol. 2008 Oct;54(4):775-6. doi: 10.1016/j.eururo.2008.06.017. Epub 2008 Jun 13.
引用本文的文献
1
Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.与良性前列腺增生相关的下尿路症状的实际医疗管理：意大利大量男性人群中5年处方率和住院率的时间趋势
Int Urol Nephrol. 2014 Apr;46(4):695-701. doi: 10.1007/s11255-013-0587-8. Epub 2013 Oct 18.
本文引用的文献
1
Characteristics of patients presenting with LUTS/BPH in six European countries.六个欧洲国家中出现下尿路症状/良性前列腺增生患者的特征。
Eur Urol. 2006 Sep;50(3):555-61; discussion 562. doi: 10.1016/j.eururo.2006.05.001. Epub 2006 May 19.
2
The cost of treating the 10 most prevalent diseases in men 50 years of age or older.50岁及以上男性中10种最常见疾病的治疗费用。
Am J Manag Care. 2006 Mar;12(4 Suppl):S90-8.
3
The development of human benign prostatic hyperplasia with age.人类良性前列腺增生随年龄的发展。
J Urol. 1984 Sep;132(3):474-9. doi: 10.1016/s0022-5347(17)49698-4.
Zotero 插件